Medical network on July 17 - national medicine, China resources, department of medicine, kyushu system, will be competing in the market of shandong!
On July 14, shandong food drug administration issued "about further promote transformation and upgrading of medicine circulation industry innovation and development of opinion (draft)" (hereinafter referred to as the exposure draft). Its core content and the guidance of the state council and the ministry of commerce of drug circulation market.
In this, the author will these points one by one, a dark day seem bright, just as for the field.
▍ characters, China resources, department of medicine, kyushu system, break into shandong
The paper first: to promote the drug circulation enterprise merger restructuring, joint development, nurturing large-scale modern medicine circulation backbone enterprises.
More clear about the government's policy support of circulation enterprise merger and reorganization, such as simplifying the relevant formalities, relax restrictions, for medicine circulation enterprises, especially large circulation enterprises in shandong market their open the door, in another ways, of course, for local small and medium circulation enterprises in shandong, will face a more difficult market choice.
From the point of the current situation, the future of its system, China resources, department of medicine, kyushu in the national market concentration will increase further, as a traditional medicine in shandong province, is certainly a few big battleground.
▍ small and medium circulation enterprises, be embraced, or driven to a corner
The future development of small and medium circulation enterprises are only two ways: either as a few big circulation channel distribution of giant enterprises, or go specialization and differentiation, such as focusing on a certain field of a disease or a segment of the market such as high-end new apt. Want to continue the past conveniently small pattern, is clearly unsustainable, word is either be consigned, either retreat to the corner.
From the point of the paper, to estimate the future for a period of time, shandong medicine circulation market will face a new round of merger and reorganization.
"Draft" the second "third-party logistics business supports drugs" and article 3 of the "encourage drug-handling enterprise cross-regional distribution", in a sense this is for large circulation enterprises in shandong market share clear policy barriers.
▍ outside prescriptions, hospital pharmacy and medicine at nus fast one step
Article 4 of the "draft" core "explore new model" drugs circulation is three aspects.
One aspect is on the premise of the computer system integration, "allow group in production, management of drugs in drugs straight" "pharmaceutical production enterprise with its Settings are allowed only sale this enterprise product management companies share the finished goods warehouse" "allow for modern logistics of pharmaceutical wholesale enterprises group synergy".
This a few "allow" is a great good to large logistics group, will further promote large pharmaceutical logistics enterprise cost savings, greatly improve synergies;
The second aspect is to encourage pharmaceutical circulation enterprises integration of wholesale and retail business.
Be worth what carry is, on the integration of retail, the characters and the department of medicine has come to the front. The current pharmacy at nus although the pace of mergers and acquisitions has slowed, but in the retail market are determined to be reckoned with, and to undertake corresponding hospital prescription of DTC pharmacy, pharmacy and medicine department of pharmacy at nus attaches great importance to and actively promote. As they state, grasp of the country's policy is particularly fast one step;
The third aspect is to slow disease management and the loosening of prescription management, especially can "by retained the prescription of sales for the first time" this is in part to loosen prescription drug sales in retail pharmacies, especially for the treatment of chronic prescription drug sales in pharmacy is a huge positive.
▍ traced back to the state council document no. 13
Through the above simple reading, we can see that the recent series of the reform of the pharmaceutical industry policy, whether national or province, can the general office of the state council on further reform and improve the pharmaceutical production circulation use policy several opinions (13) found in the source, so the author suggested that the industry is to carefully read this file.
Its actual content has been involved in the top design, the entire pharmaceutical industry files on the pharmaceutical industry is we have to grasp the direction of the future development. |
